Skip to Content
You are currently on the new version of our website. Access the old version .
MedicinaMedicina
  • Systematic Review
  • Open Access

23 September 2025

12 Pages

Opioid-Associated Postoperative Nausea and Vomiting in Women Undergoing Laparoscopic Hysterectomy: A Network Meta-Analysis

,
,
,
,
,
and
1
Research Institute of Pharmaceutical Sciences, Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea
2
College of Pharmacy, Jeju National University, Jeju 63241, Republic of Korea
3
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
4
Department of Anesthesiology, University of Southern California, Los Angeles, CA 90033, USA
This article belongs to the Section Intensive Care/ Anesthesiology

Abstract

Background and Objectives: This systematic review and network meta-analysis evaluated the effects of postoperative opioid use on nausea and vomiting in women undergoing laparoscopic hysterectomy. Materials and Methods: A systematic search of PubMed, EMBASE, the Cochrane Library, and RISS was conducted to identify randomized controlled trials that met the eligibility criteria. The Cochrane Risk of Bias 2 tool was used to assess the quality of the included studies. A frequentist network meta-analysis was performed to compare the risks of opioid-associated postoperative nausea and vomiting (O-PONV). Quantitative statistics were presented in forest plots, and the ranking of treatments was determined using the P-score. Results: Seventeen studies involving 1315 participants and 18 postoperative analgesic interventions were included. No significant differences were found among the opioid monotherapies—buprenorphine, butorphanol, fentanyl, oxycodone, sufentanil, and tapentadol. However, among the combination therapies, oxycodone/ketorolac therapy was associated with a significantly higher risk of O-PONV than other ketorolac-containing regimens, including dexmedetomidine, remifentanil, and fentanyl. Conclusions: No significant differences in O-PONV risk were observed among the six opioid monotherapy groups. An opioid-sparing regimen, such as dexmedetomidine/ketorolac, showed a lower risk of O-PONV than an oxycodone-based regimen, underscoring the importance of incorporating patient-centered considerations, such as patient preference and route of administration, into postoperative pain management.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.